nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Dry skin—Fluorouracil—skin cancer	0.00275	0.00275	CcSEcCtD
Milnacipran—Dry mouth—Imiquimod—skin cancer	0.00272	0.00272	CcSEcCtD
Milnacipran—Decreased appetite—Vemurafenib—skin cancer	0.00272	0.00272	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vemurafenib—skin cancer	0.0027	0.0027	CcSEcCtD
Milnacipran—Fatigue—Vemurafenib—skin cancer	0.0027	0.0027	CcSEcCtD
Milnacipran—Constipation—Vemurafenib—skin cancer	0.00267	0.00267	CcSEcCtD
Milnacipran—Hypoaesthesia—Bleomycin—skin cancer	0.00265	0.00265	CcSEcCtD
Milnacipran—Infection—Imiquimod—skin cancer	0.00265	0.00265	CcSEcCtD
Milnacipran—Dysuria—Temozolomide—skin cancer	0.00263	0.00263	CcSEcCtD
Milnacipran—Neutropenia—Temozolomide—skin cancer	0.00263	0.00263	CcSEcCtD
Milnacipran—Shock—Imiquimod—skin cancer	0.00262	0.00262	CcSEcCtD
Milnacipran—Nervous system disorder—Imiquimod—skin cancer	0.00261	0.00261	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Temozolomide—skin cancer	0.00261	0.00261	CcSEcCtD
Milnacipran—Tachycardia—Imiquimod—skin cancer	0.0026	0.0026	CcSEcCtD
Milnacipran—Pollakiuria—Temozolomide—skin cancer	0.0026	0.0026	CcSEcCtD
Milnacipran—Skin disorder—Imiquimod—skin cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Erectile dysfunction—Temozolomide—skin cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Hyperhidrosis—Imiquimod—skin cancer	0.00258	0.00258	CcSEcCtD
Milnacipran—Weight decreased—Temozolomide—skin cancer	0.00254	0.00254	CcSEcCtD
Milnacipran—Anorexia—Imiquimod—skin cancer	0.00254	0.00254	CcSEcCtD
Milnacipran—Angina pectoris—Fluorouracil—skin cancer	0.00252	0.00252	CcSEcCtD
Milnacipran—Hepatitis—Dactinomycin—skin cancer	0.00249	0.00249	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00248	0.00248	CcSEcCtD
Milnacipran—Flushing—Bleomycin—skin cancer	0.00247	0.00247	CcSEcCtD
Milnacipran—Body temperature increased—Vemurafenib—skin cancer	0.00247	0.00247	CcSEcCtD
Milnacipran—Urinary tract infection—Temozolomide—skin cancer	0.00244	0.00244	CcSEcCtD
Milnacipran—Insomnia—Imiquimod—skin cancer	0.00241	0.00241	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00241	0.00241	CcSEcCtD
Milnacipran—Paraesthesia—Imiquimod—skin cancer	0.00239	0.00239	CcSEcCtD
Milnacipran—Chills—Bleomycin—skin cancer	0.00239	0.00239	CcSEcCtD
Milnacipran—Dyspnoea—Imiquimod—skin cancer	0.00238	0.00238	CcSEcCtD
Milnacipran—Somnolence—Imiquimod—skin cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Hepatobiliary disease—Temozolomide—skin cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Erythema multiforme—Dactinomycin—skin cancer	0.00235	0.00235	CcSEcCtD
Milnacipran—Dyspepsia—Imiquimod—skin cancer	0.00235	0.00235	CcSEcCtD
Milnacipran—Decreased appetite—Imiquimod—skin cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Hot flush—Docetaxel—skin cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Flushing—Dactinomycin—skin cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Hypersensitivity—Vemurafenib—skin cancer	0.0023	0.0023	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Imiquimod—skin cancer	0.0023	0.0023	CcSEcCtD
Milnacipran—Fatigue—Imiquimod—skin cancer	0.0023	0.0023	CcSEcCtD
Milnacipran—Menopausal symptoms—Docetaxel—skin cancer	0.00229	0.00229	CcSEcCtD
Milnacipran—Hepatitis—Temozolomide—skin cancer	0.00225	0.00225	CcSEcCtD
Milnacipran—Urinary tract infection—Fluorouracil—skin cancer	0.00224	0.00224	CcSEcCtD
Milnacipran—Asthenia—Vemurafenib—skin cancer	0.00224	0.00224	CcSEcCtD
Milnacipran—Hallucination—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Milnacipran—Hypoaesthesia—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Milnacipran—Chills—Dactinomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Milnacipran—Urinary tract disorder—Temozolomide—skin cancer	0.00222	0.00222	CcSEcCtD
Milnacipran—Oedema peripheral—Temozolomide—skin cancer	0.00222	0.00222	CcSEcCtD
Milnacipran—Pruritus—Vemurafenib—skin cancer	0.00221	0.00221	CcSEcCtD
Milnacipran—Connective tissue disorder—Temozolomide—skin cancer	0.00221	0.00221	CcSEcCtD
Milnacipran—Urethral disorder—Temozolomide—skin cancer	0.0022	0.0022	CcSEcCtD
Milnacipran—Gastrointestinal pain—Imiquimod—skin cancer	0.00218	0.00218	CcSEcCtD
Milnacipran—Hyponatraemia—Docetaxel—skin cancer	0.00217	0.00217	CcSEcCtD
Milnacipran—Diarrhoea—Vemurafenib—skin cancer	0.00214	0.00214	CcSEcCtD
Milnacipran—Migraine—Docetaxel—skin cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Erythema multiforme—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Urticaria—Imiquimod—skin cancer	0.00212	0.00212	CcSEcCtD
Milnacipran—Body temperature increased—Imiquimod—skin cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Abdominal pain—Imiquimod—skin cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Eye disorder—Temozolomide—skin cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Cardiac disorder—Temozolomide—skin cancer	0.00209	0.00209	CcSEcCtD
Milnacipran—Flushing—Temozolomide—skin cancer	0.00209	0.00209	CcSEcCtD
Milnacipran—Leukopenia—Bleomycin—skin cancer	0.00208	0.00208	CcSEcCtD
Milnacipran—Dizziness—Vemurafenib—skin cancer	0.00207	0.00207	CcSEcCtD
Milnacipran—Hypoaesthesia—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Milnacipran—Angiopathy—Temozolomide—skin cancer	0.00204	0.00204	CcSEcCtD
Milnacipran—Mediastinal disorder—Temozolomide—skin cancer	0.00203	0.00203	CcSEcCtD
Milnacipran—Chills—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Milnacipran—Liver function test abnormal—Docetaxel—skin cancer	0.002	0.002	CcSEcCtD
Milnacipran—Vomiting—Vemurafenib—skin cancer	0.00199	0.00199	CcSEcCtD
Milnacipran—Dry skin—Docetaxel—skin cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Chest pain—Bleomycin—skin cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Rash—Vemurafenib—skin cancer	0.00197	0.00197	CcSEcCtD
Milnacipran—Mental disorder—Temozolomide—skin cancer	0.00197	0.00197	CcSEcCtD
Milnacipran—Dermatitis—Vemurafenib—skin cancer	0.00197	0.00197	CcSEcCtD
Milnacipran—Hypersensitivity—Imiquimod—skin cancer	0.00196	0.00196	CcSEcCtD
Milnacipran—Headache—Vemurafenib—skin cancer	0.00196	0.00196	CcSEcCtD
Milnacipran—Malnutrition—Temozolomide—skin cancer	0.00196	0.00196	CcSEcCtD
Milnacipran—Breast disorder—Docetaxel—skin cancer	0.00195	0.00195	CcSEcCtD
Milnacipran—Leukopenia—Dactinomycin—skin cancer	0.00194	0.00194	CcSEcCtD
Milnacipran—Dysgeusia—Temozolomide—skin cancer	0.00192	0.00192	CcSEcCtD
Milnacipran—Asthenia—Imiquimod—skin cancer	0.00191	0.00191	CcSEcCtD
Milnacipran—Pruritus—Imiquimod—skin cancer	0.00189	0.00189	CcSEcCtD
Milnacipran—Infection—Bleomycin—skin cancer	0.00188	0.00188	CcSEcCtD
Milnacipran—Nausea—Vemurafenib—skin cancer	0.00186	0.00186	CcSEcCtD
Milnacipran—Thrombocytopenia—Bleomycin—skin cancer	0.00185	0.00185	CcSEcCtD
Milnacipran—Vision blurred—Temozolomide—skin cancer	0.00185	0.00185	CcSEcCtD
Milnacipran—Tremor—Temozolomide—skin cancer	0.00183	0.00183	CcSEcCtD
Milnacipran—Diarrhoea—Imiquimod—skin cancer	0.00182	0.00182	CcSEcCtD
Milnacipran—Angina pectoris—Docetaxel—skin cancer	0.00182	0.00182	CcSEcCtD
Milnacipran—Anorexia—Bleomycin—skin cancer	0.00181	0.00181	CcSEcCtD
Milnacipran—Agitation—Temozolomide—skin cancer	0.0018	0.0018	CcSEcCtD
Milnacipran—Hypotension—Bleomycin—skin cancer	0.00177	0.00177	CcSEcCtD
Milnacipran—Dizziness—Imiquimod—skin cancer	0.00176	0.00176	CcSEcCtD
Milnacipran—Infection—Dactinomycin—skin cancer	0.00175	0.00175	CcSEcCtD
Milnacipran—Leukopenia—Temozolomide—skin cancer	0.00175	0.00175	CcSEcCtD
Milnacipran—Neutropenia—Docetaxel—skin cancer	0.00175	0.00175	CcSEcCtD
Milnacipran—Palpitations—Temozolomide—skin cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Thrombocytopenia—Dactinomycin—skin cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Paraesthesia—Bleomycin—skin cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Vision blurred—Fluorouracil—skin cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Convulsion—Temozolomide—skin cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Vomiting—Imiquimod—skin cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Weight decreased—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Hypertension—Temozolomide—skin cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Dyspnoea—Bleomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Anorexia—Dactinomycin—skin cancer	0.00168	0.00168	CcSEcCtD
Milnacipran—Rash—Imiquimod—skin cancer	0.00168	0.00168	CcSEcCtD
Milnacipran—Dermatitis—Imiquimod—skin cancer	0.00168	0.00168	CcSEcCtD
Milnacipran—Headache—Imiquimod—skin cancer	0.00167	0.00167	CcSEcCtD
Milnacipran—Anxiety—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
Milnacipran—Decreased appetite—Bleomycin—skin cancer	0.00165	0.00165	CcSEcCtD
Milnacipran—Dry mouth—Temozolomide—skin cancer	0.00163	0.00163	CcSEcCtD
Milnacipran—Leukopenia—Fluorouracil—skin cancer	0.00161	0.00161	CcSEcCtD
Milnacipran—Infection—Temozolomide—skin cancer	0.00159	0.00159	CcSEcCtD
Milnacipran—Nausea—Imiquimod—skin cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Hepatobiliary disease—Docetaxel—skin cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Nervous system disorder—Temozolomide—skin cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Thrombocytopenia—Temozolomide—skin cancer	0.00156	0.00156	CcSEcCtD
Milnacipran—Convulsion—Fluorouracil—skin cancer	0.00156	0.00156	CcSEcCtD
Milnacipran—Skin disorder—Temozolomide—skin cancer	0.00155	0.00155	CcSEcCtD
Milnacipran—Hyperhidrosis—Temozolomide—skin cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Chest pain—Fluorouracil—skin cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Decreased appetite—Dactinomycin—skin cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Fatigue—Dactinomycin—skin cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Anorexia—Temozolomide—skin cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Urticaria—Bleomycin—skin cancer	0.0015	0.0015	CcSEcCtD
Milnacipran—Body temperature increased—Bleomycin—skin cancer	0.0015	0.0015	CcSEcCtD
Milnacipran—Hepatitis—Docetaxel—skin cancer	0.0015	0.0015	CcSEcCtD
Milnacipran—Hypoaesthesia—Docetaxel—skin cancer	0.00149	0.00149	CcSEcCtD
Milnacipran—Urinary tract disorder—Docetaxel—skin cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Oedema peripheral—Docetaxel—skin cancer	0.00147	0.00147	CcSEcCtD
Milnacipran—Connective tissue disorder—Docetaxel—skin cancer	0.00147	0.00147	CcSEcCtD
Milnacipran—Urethral disorder—Docetaxel—skin cancer	0.00147	0.00147	CcSEcCtD
Milnacipran—Infection—Fluorouracil—skin cancer	0.00146	0.00146	CcSEcCtD
Milnacipran—Insomnia—Temozolomide—skin cancer	0.00145	0.00145	CcSEcCtD
Milnacipran—Gastrointestinal pain—Dactinomycin—skin cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Nervous system disorder—Fluorouracil—skin cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Thrombocytopenia—Fluorouracil—skin cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Tachycardia—Fluorouracil—skin cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Paraesthesia—Temozolomide—skin cancer	0.00143	0.00143	CcSEcCtD
Milnacipran—Dyspnoea—Temozolomide—skin cancer	0.00142	0.00142	CcSEcCtD
Milnacipran—Somnolence—Temozolomide—skin cancer	0.00142	0.00142	CcSEcCtD
Milnacipran—Erythema multiforme—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Milnacipran—Dyspepsia—Temozolomide—skin cancer	0.00141	0.00141	CcSEcCtD
Milnacipran—Anorexia—Fluorouracil—skin cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Eye disorder—Docetaxel—skin cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Abdominal pain—Dactinomycin—skin cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Body temperature increased—Dactinomycin—skin cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Hypersensitivity—Bleomycin—skin cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Decreased appetite—Temozolomide—skin cancer	0.00139	0.00139	CcSEcCtD
Milnacipran—Flushing—Docetaxel—skin cancer	0.00139	0.00139	CcSEcCtD
Milnacipran—Cardiac disorder—Docetaxel—skin cancer	0.00139	0.00139	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Temozolomide—skin cancer	0.00138	0.00138	CcSEcCtD
Milnacipran—Fatigue—Temozolomide—skin cancer	0.00138	0.00138	CcSEcCtD
Milnacipran—Hypotension—Fluorouracil—skin cancer	0.00138	0.00138	CcSEcCtD
Milnacipran—Constipation—Temozolomide—skin cancer	0.00137	0.00137	CcSEcCtD
Milnacipran—Asthenia—Bleomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Milnacipran—Angiopathy—Docetaxel—skin cancer	0.00136	0.00136	CcSEcCtD
Milnacipran—Mediastinal disorder—Docetaxel—skin cancer	0.00135	0.00135	CcSEcCtD
Milnacipran—Chills—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Milnacipran—Pruritus—Bleomycin—skin cancer	0.00134	0.00134	CcSEcCtD
Milnacipran—Insomnia—Fluorouracil—skin cancer	0.00133	0.00133	CcSEcCtD
Milnacipran—Paraesthesia—Fluorouracil—skin cancer	0.00132	0.00132	CcSEcCtD
Milnacipran—Dyspnoea—Fluorouracil—skin cancer	0.00131	0.00131	CcSEcCtD
Milnacipran—Mental disorder—Docetaxel—skin cancer	0.00131	0.00131	CcSEcCtD
Milnacipran—Somnolence—Fluorouracil—skin cancer	0.00131	0.00131	CcSEcCtD
Milnacipran—Gastrointestinal pain—Temozolomide—skin cancer	0.00131	0.00131	CcSEcCtD
Milnacipran—Malnutrition—Docetaxel—skin cancer	0.0013	0.0013	CcSEcCtD
Milnacipran—Hypersensitivity—Dactinomycin—skin cancer	0.0013	0.0013	CcSEcCtD
Milnacipran—Dyspepsia—Fluorouracil—skin cancer	0.0013	0.0013	CcSEcCtD
Milnacipran—Decreased appetite—Fluorouracil—skin cancer	0.00128	0.00128	CcSEcCtD
Milnacipran—Dysgeusia—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00127	0.00127	CcSEcCtD
Milnacipran—Urticaria—Temozolomide—skin cancer	0.00127	0.00127	CcSEcCtD
Milnacipran—Asthenia—Dactinomycin—skin cancer	0.00127	0.00127	CcSEcCtD
Milnacipran—Body temperature increased—Temozolomide—skin cancer	0.00126	0.00126	CcSEcCtD
Milnacipran—Abdominal pain—Temozolomide—skin cancer	0.00126	0.00126	CcSEcCtD
Milnacipran—Diarrhoea—Dactinomycin—skin cancer	0.00121	0.00121	CcSEcCtD
Milnacipran—Vomiting—Bleomycin—skin cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Rash—Bleomycin—skin cancer	0.00119	0.00119	CcSEcCtD
Milnacipran—Dermatitis—Bleomycin—skin cancer	0.00119	0.00119	CcSEcCtD
Milnacipran—Hypersensitivity—Temozolomide—skin cancer	0.00118	0.00118	CcSEcCtD
Milnacipran—Urticaria—Fluorouracil—skin cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Syncope—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Leukopenia—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Body temperature increased—Fluorouracil—skin cancer	0.00116	0.00116	CcSEcCtD
Milnacipran—Palpitations—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Milnacipran—Asthenia—Temozolomide—skin cancer	0.00115	0.00115	CcSEcCtD
Milnacipran—Loss of consciousness—Docetaxel—skin cancer	0.00114	0.00114	CcSEcCtD
Milnacipran—Pruritus—Temozolomide—skin cancer	0.00113	0.00113	CcSEcCtD
Milnacipran—Convulsion—Docetaxel—skin cancer	0.00113	0.00113	CcSEcCtD
Milnacipran—Nausea—Bleomycin—skin cancer	0.00113	0.00113	CcSEcCtD
Milnacipran—Hypertension—Docetaxel—skin cancer	0.00112	0.00112	CcSEcCtD
Milnacipran—Vomiting—Dactinomycin—skin cancer	0.00112	0.00112	CcSEcCtD
Milnacipran—Rash—Dactinomycin—skin cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Chest pain—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Milnacipran—Diarrhoea—Temozolomide—skin cancer	0.00109	0.00109	CcSEcCtD
Milnacipran—Hypersensitivity—Fluorouracil—skin cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Dry mouth—Docetaxel—skin cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Dizziness—Temozolomide—skin cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Infection—Docetaxel—skin cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Nausea—Dactinomycin—skin cancer	0.00105	0.00105	CcSEcCtD
Milnacipran—Shock—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
Milnacipran—Nervous system disorder—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Pruritus—Fluorouracil—skin cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Thrombocytopenia—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Tachycardia—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Skin disorder—Docetaxel—skin cancer	0.00103	0.00103	CcSEcCtD
Milnacipran—Vomiting—Temozolomide—skin cancer	0.00102	0.00102	CcSEcCtD
Milnacipran—Anorexia—Docetaxel—skin cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Rash—Temozolomide—skin cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Diarrhoea—Fluorouracil—skin cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Dermatitis—Temozolomide—skin cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Headache—Temozolomide—skin cancer	0.001	0.001	CcSEcCtD
Milnacipran—Hypotension—Docetaxel—skin cancer	0.000993	0.000993	CcSEcCtD
Milnacipran—Dizziness—Fluorouracil—skin cancer	0.000973	0.000973	CcSEcCtD
Milnacipran—Insomnia—Docetaxel—skin cancer	0.000961	0.000961	CcSEcCtD
Milnacipran—Paraesthesia—Docetaxel—skin cancer	0.000954	0.000954	CcSEcCtD
Milnacipran—Nausea—Temozolomide—skin cancer	0.000949	0.000949	CcSEcCtD
Milnacipran—Dyspnoea—Docetaxel—skin cancer	0.000947	0.000947	CcSEcCtD
Milnacipran—Somnolence—Docetaxel—skin cancer	0.000945	0.000945	CcSEcCtD
Milnacipran—Vomiting—Fluorouracil—skin cancer	0.000936	0.000936	CcSEcCtD
Milnacipran—Dyspepsia—Docetaxel—skin cancer	0.000935	0.000935	CcSEcCtD
Milnacipran—Rash—Fluorouracil—skin cancer	0.000928	0.000928	CcSEcCtD
Milnacipran—Dermatitis—Fluorouracil—skin cancer	0.000927	0.000927	CcSEcCtD
Milnacipran—Decreased appetite—Docetaxel—skin cancer	0.000924	0.000924	CcSEcCtD
Milnacipran—Headache—Fluorouracil—skin cancer	0.000922	0.000922	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Docetaxel—skin cancer	0.000917	0.000917	CcSEcCtD
Milnacipran—Fatigue—Docetaxel—skin cancer	0.000916	0.000916	CcSEcCtD
Milnacipran—Constipation—Docetaxel—skin cancer	0.000909	0.000909	CcSEcCtD
Milnacipran—Nausea—Fluorouracil—skin cancer	0.000874	0.000874	CcSEcCtD
Milnacipran—Gastrointestinal pain—Docetaxel—skin cancer	0.000869	0.000869	CcSEcCtD
Milnacipran—Abdominal pain—Docetaxel—skin cancer	0.00084	0.00084	CcSEcCtD
Milnacipran—Body temperature increased—Docetaxel—skin cancer	0.00084	0.00084	CcSEcCtD
Milnacipran—Hypersensitivity—Docetaxel—skin cancer	0.000783	0.000783	CcSEcCtD
Milnacipran—Asthenia—Docetaxel—skin cancer	0.000762	0.000762	CcSEcCtD
Milnacipran—Pruritus—Docetaxel—skin cancer	0.000752	0.000752	CcSEcCtD
Milnacipran—Diarrhoea—Docetaxel—skin cancer	0.000727	0.000727	CcSEcCtD
Milnacipran—Dizziness—Docetaxel—skin cancer	0.000703	0.000703	CcSEcCtD
Milnacipran—Vomiting—Docetaxel—skin cancer	0.000676	0.000676	CcSEcCtD
Milnacipran—Rash—Docetaxel—skin cancer	0.00067	0.00067	CcSEcCtD
Milnacipran—Dermatitis—Docetaxel—skin cancer	0.000669	0.000669	CcSEcCtD
Milnacipran—Headache—Docetaxel—skin cancer	0.000666	0.000666	CcSEcCtD
Milnacipran—Nausea—Docetaxel—skin cancer	0.000631	0.000631	CcSEcCtD
